GT Biopharma Files 8-K: Security Holder Rights, Bylaw Amendments
Ticker: GTBP · Form: 8-K · Filed: Feb 1, 2024 · CIK: 109657
| Field | Detail |
|---|---|
| Company | Gt Biopharma, INC. (GTBP) |
| Form Type | 8-K |
| Filed Date | Feb 1, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: corporate-governance, shareholder-rights, bylaw-amendment
TL;DR
**GT Biopharma just filed an 8-K about changes to shareholder rights and bylaws, so watch out for potential dilution or governance shifts.**
AI Summary
GT Biopharma, Inc. filed an 8-K on February 1, 2024, to report material modifications to the rights of its security holders and amendments to its Articles of Incorporation or Bylaws. This filing indicates potential changes that could impact existing shareholders' ownership stakes or voting power, as well as the company's operational framework. Investors should be aware that such changes could dilute their shares or alter corporate governance, potentially affecting the stock's value.
Why It Matters
Changes to security holder rights or company bylaws can directly impact shareholder value and control, making it crucial for investors to understand the specifics of these modifications.
Risk Assessment
Risk Level: medium — Modifications to security holder rights and bylaws can introduce uncertainty regarding shareholder value and corporate control, posing a medium risk to investors.
Analyst Insight
A smart investor would closely monitor GT Biopharma's subsequent filings (e.g., 10-K, 10-Q, or other 8-Ks) for specific details regarding the modifications to security holder rights and bylaws to assess potential impacts on their investment.
Key Players & Entities
- GT Biopharma, Inc. (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for GT Biopharma, Inc.
- February 1, 2024 (date) — date of earliest event reported in the 8-K filing
- 8000 Marina Blvd., Suite 100, Brisbane, CA 94005 (company) — principal executive offices of GT Biopharma, Inc.
- (800) 304-9888 (company) — registrant's telephone number
Forward-Looking Statements
- GT Biopharma, Inc. will provide further details on the specific modifications to security holder rights and bylaws in subsequent filings or communications. (GT Biopharma, Inc.) — medium confidence, target: 2024-03-31
FAQ
What is the primary purpose of GT Biopharma, Inc.'s 8-K filing on February 1, 2024?
The primary purpose of GT Biopharma, Inc.'s 8-K filing on February 1, 2024, is to report material modifications to the rights of security holders and amendments to its Articles of Incorporation or Bylaws, as indicated by Item Information sections.
What is the earliest event date reported in this 8-K filing?
The earliest event reported in this 8-K filing is February 1, 2024, as stated under 'Date of Report: (Date of earliest event reported)'.
Where are GT Biopharma, Inc.'s principal executive offices located?
GT Biopharma, Inc.'s principal executive offices are located at 8000 Marina Blvd., Suite 100, Brisbane, CA 94005.
What is GT Biopharma, Inc.'s state of incorporation?
GT Biopharma, Inc.'s state of incorporation is Delaware.
What is the company's Central Index Key (CIK) according to the filing?
The company's Central Index Key (CIK) is 0000109657, as listed in the COMPANY DATA section.
Filing Stats: 1,004 words · 4 min read · ~3 pages · Grade level 10.4 · Accepted 2024-02-01 12:15:12
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex3-1.htm (EX-3.1) — 12KB
- ex99-1.htm (EX-99.1) — 16KB
- 0001493152-24-004587.txt ( ) — 251KB
- gtbp-20240201.xsd (EX-101.SCH) — 3KB
- gtbp-20240201_lab.xml (EX-101.LAB) — 33KB
- gtbp-20240201_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: February 1, 2024 By: /s/ Manu Ohri Manu Ohri Chief Financial Officer